Sees FY23 revenue $8.83B-$9.03B, consensus $9.13B. Sees FY23 cash provided by operations at least $1.3B. Sees FY23 capital expenditures $400M. "In 2023, our focus is on growing our base business and increasing our efforts to drive productivity and expand margins. Our guidance for the full year reflects continued growth in the base business, tailwinds from recent Medicare reimbursement changes, investments to accelerate growth, and declining COVID-19 revenues."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2023
- Agilent, Quest team to extend access to Resolution ctDx FIRST NGS test
- Quest Diagnostics initiated with an In Line at Evercore ISI
- Quest Diagnostics price target raised to $154 from $143 at Baird
- Doctors gain confidence in new Alzheimer’s blood tests, Bloomberg reports